PT2252301E - Utilização de ulipristal para tratar fibromas uterinos - Google Patents

Utilização de ulipristal para tratar fibromas uterinos Download PDF

Info

Publication number
PT2252301E
PT2252301E PT97063473T PT09706347T PT2252301E PT 2252301 E PT2252301 E PT 2252301E PT 97063473 T PT97063473 T PT 97063473T PT 09706347 T PT09706347 T PT 09706347T PT 2252301 E PT2252301 E PT 2252301E
Authority
PT
Portugal
Prior art keywords
ulipristal
uterine fibroids
treating uterine
treating
fibroids
Prior art date
Application number
PT97063473T
Other languages
English (en)
Portuguese (pt)
Inventor
Andre Ulmann
Erin Gainer
Lynnette Nieman
Diana Blithe
Original Assignee
Hra Pharma Lab
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2252301(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab, Us Health filed Critical Hra Pharma Lab
Publication of PT2252301E publication Critical patent/PT2252301E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PT97063473T 2008-01-29 2009-01-28 Utilização de ulipristal para tratar fibromas uterinos PT2252301E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids

Publications (1)

Publication Number Publication Date
PT2252301E true PT2252301E (pt) 2014-02-24

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97063473T PT2252301E (pt) 2008-01-29 2009-01-28 Utilização de ulipristal para tratar fibromas uterinos

Country Status (20)

Country Link
US (5) US8299050B2 (enExample)
EP (2) EP2684565B1 (enExample)
JP (2) JP5906016B2 (enExample)
KR (2) KR20150055626A (enExample)
AU (1) AU2009209652B2 (enExample)
BR (1) BRPI0907028B8 (enExample)
CA (2) CA2857798A1 (enExample)
CY (1) CY1116485T1 (enExample)
DK (1) DK2252301T3 (enExample)
ES (1) ES2450592T3 (enExample)
HR (1) HRP20140132T1 (enExample)
IL (2) IL207182A (enExample)
MX (1) MX2010008270A (enExample)
NZ (1) NZ587439A (enExample)
PL (1) PL2252301T3 (enExample)
PT (1) PT2252301E (enExample)
SI (1) SI2252301T1 (enExample)
TW (1) TWI445537B (enExample)
WO (1) WO2009095418A1 (enExample)
ZA (1) ZA201006049B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
PH12012501812A1 (en) * 2010-03-22 2012-12-10 Allergan Pharmaceuticals Int Ltd Compositions and methods for non-toxic delivery of antiprogestins
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
HK1213487A1 (zh) * 2012-12-14 2016-07-08 The Population Council, Inc. 銅子宮環
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
CA2941010A1 (en) * 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
JP2016516764A (ja) 2013-04-10 2016-06-09 プレグレム ソシエテ アノニム 子宮筋腫治療に用いるプロゲステロン受容体調節剤
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
JP2018502061A (ja) * 2014-11-24 2018-01-25 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． 子宮筋腫の治療のための色素上皮由来因子（ｐｅｄｆ）
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
WO2021166001A1 (en) 2020-02-19 2021-08-26 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DK0806952T3 (da) * 1995-02-02 2003-06-16 Schering Ag Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
AU747710B2 (en) * 1997-11-14 2002-05-23 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
KR101229701B1 (ko) 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
WO2007038796A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
AU2007339820A1 (en) 2006-12-28 2008-07-10 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
US8569274B2 (en) 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
US20090192130A1 (en) 2009-07-30
US9682088B2 (en) 2017-06-20
BRPI0907028A8 (pt) 2019-08-13
JP2011510949A (ja) 2011-04-07
EP2684565B1 (en) 2019-10-02
ZA201006049B (en) 2011-05-25
EP2684565A1 (en) 2014-01-15
EP2252301A1 (en) 2010-11-24
CA2857798A1 (en) 2009-09-06
ES2450592T3 (es) 2014-03-25
IL207182A (en) 2015-06-30
AU2009209652A1 (en) 2009-08-06
US8299050B2 (en) 2012-10-30
HRP20140132T1 (hr) 2014-05-09
US20130023506A1 (en) 2013-01-24
TW200944211A (en) 2009-11-01
IL207182A0 (en) 2010-12-30
NZ587439A (en) 2012-06-29
US20170246189A1 (en) 2017-08-31
MX2010008270A (es) 2011-01-14
US8722653B2 (en) 2014-05-13
JP2015120711A (ja) 2015-07-02
EP2252301B1 (en) 2013-12-11
CA2713254C (en) 2014-10-07
DK2252301T3 (en) 2014-02-17
US20140187525A1 (en) 2014-07-03
IL234149B (en) 2019-02-28
US9180133B2 (en) 2015-11-10
IL234149A0 (en) 2014-09-30
BRPI0907028B1 (pt) 2019-09-24
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
CY1116485T1 (el) 2017-03-15
KR101571400B1 (ko) 2015-11-24
KR20110021709A (ko) 2011-03-04
BRPI0907028A2 (pt) 2015-07-07
CA2713254A1 (en) 2009-09-06
BRPI0907028B8 (pt) 2021-05-25
AU2009209652B2 (en) 2013-03-21
KR20150055626A (ko) 2015-05-21
TWI445537B (zh) 2014-07-21
PL2252301T3 (pl) 2014-07-31
WO2009095418A1 (en) 2009-08-06
JP6138838B2 (ja) 2017-05-31
JP5906016B2 (ja) 2016-04-20

Similar Documents

Publication Publication Date Title
ZA201006049B (en) Use of ulipristal for treating uterine fibroids
IL215767A0 (en) Methods of treatment for solid tumors
EP2521724A4 (en) ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES
EP2552546A4 (en) OFFICE COMPATIBLE SYSTEM FOR THE TREATMENT OF NUTRITIONAL FIBROMES OR OTHER WOVEN FABRICS WITH HIFU
GB0803514D0 (en) Customised surgical apparatus
PT2252148T (pt) Métodos de tratamento da síndrome do intestino irritável
IL208354A0 (en) Methods of treatment
IL207892A0 (en) Agent for treating disease
IL207890A0 (en) Agent for treating disease
IL207891A0 (en) Agent for treating disease
PL2473592T3 (pl) Zastosowanie środków do traktowania twardych powierzchni
ZA201204845B (en) Agents for treating disease
EP2327974A4 (en) TISSUE TREATMENT DEVICE
GB2470708B (en) Device for morcellating tissue
GB0821097D0 (en) Surgical device
PL2459092T3 (pl) Urządzenie do waporyzacji tkanek
EP2284515A4 (en) APPARATUS FOR TREATING A FABRIC PIECE
GB0921719D0 (en) Surgical apparatus
IL213287A0 (en) Treatment for glomerulonephritis
GB201204454D0 (en) Methods of inducing tissue regeneration
PL2249735T3 (pl) Przyrząd elektrochirurgiczny
PL2244572T3 (pl) Zastosowanie kongenerów ibogaminy do leczenia otyłości
GB0920940D0 (en) Agent for treating disease
GB0920942D0 (en) Agent for treating disease
GB0920933D0 (en) Agent for treating disease